- Home
- RPT vs SGMT Comparison
RPT vs SGMT Comparison
Compare RPT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPT
- SGMT
- Stock Information
- Founded
- RPT 2014
- SGMT 2006
- Country
- RPT United States
- SGMT United States
- Employees
- RPT N/A
- SGMT N/A
- Industry
- RPT
- SGMT
- Sector
- RPT
- SGMT
- Exchange
- RPT NYSE
- SGMT Nasdaq
- Market Cap
- RPT 139.4M
- SGMT 165.4M
- IPO Year
- RPT N/A
- SGMT 2023
- Fundamental
- Price
- RPT $3.15
- SGMT $4.12
- Analyst Decision
- RPT Strong Buy
- SGMT Strong Buy
- Analyst Count
- RPT 1
- SGMT 7
- Target Price
- RPT $4.00
- SGMT $25.71
- AVG Volume (30 Days)
- RPT 250.3K
- SGMT 877.5K
- Earning Date
- RPT 01-01-0001
- SGMT 03-24-2025
- Dividend Yield
- RPT 7.62%
- SGMT N/A
- EPS Growth
- RPT N/A
- SGMT N/A
- EPS
- RPT N/A
- SGMT N/A
- Revenue
- RPT N/A
- SGMT N/A
- Revenue This Year
- RPT N/A
- SGMT N/A
- Revenue Next Year
- RPT N/A
- SGMT N/A
- P/E Ratio
- RPT N/A
- SGMT N/A
- Revenue Growth
- RPT N/A
- SGMT N/A
- 52 Week Low
- RPT $2.65
- SGMT $2.39
- 52 Week High
- RPT $5.07
- SGMT $7.64
- Technical
- Relative Strength Index (RSI)
- RPT N/A
- SGMT 43.11
- Support Level
- RPT N/A
- SGMT $3.96
- Resistance Level
- RPT N/A
- SGMT $4.83
- Average True Range (ATR)
- RPT 0.00
- SGMT 0.38
- MACD
- RPT 0.00
- SGMT -0.04
- Stochastic Oscillator
- RPT 0.00
- SGMT 13.39
About RPT RITHM PROPERTY TRUST INC
Rithm Property Trust Inc is a real estate investment trust (REIT) externally managed by an affiliate of Rithm Capital Corp. (Rithm). The group is embarking on a new commercial real estate-focused investment. Its tailored approach to investment management seeks to generate attractive risk-adjusted returns for stockholders over the long term through dividends and capital appreciation.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).